Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lyumjev U-200 vs U-100 in Healthy Subjects
NCT03334448Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin lispro in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours. Started Dec 2017; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03334448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334448.